prohibited list comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-09-02. Numbers and descriptions here follow the published literature rather than marketing material.
Lyophilized tesamorelin is generally stored refrigerated at temperatures between 2 and 8 degrees Celsius. The solid form is comparatively stable when kept dry and protected from light. Moisture uptake can promote aggregation and degradation, so sealed containers with desiccant are common. Researchers typically avoid repeated temperature cycling, which may stress the peptide. Documentation accompanying reference materials usually specifies a shelf life under these conditions.
Once reconstituted, the peptide is handled as a solution and is less stable than the lyophilized powder. Aqueous solutions are commonly kept cold and used within a defined period. Buffer composition and pH influence degradation rates, with extremes of acidity or alkalinity accelerating hydrolysis. Preservatives may be added in multi-dose formats to limit microbial growth. Freezing and thawing of solutions is generally avoided because it can cause precipitation or loss of activity.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility | Soluble in water | Consistent with peptide nature |
| Typical storage | 2 to 8 degrees Celsius | Refrigerated, dry, protected from light |
| Common analytical method | Reversed-phase HPLC | Purity and impurity profiling |
| Identity confirmation | Mass spectrometry | Molecular mass verification |
The peptide is supplied as a lyophilized powder in single-use vials and is normally kept refrigerated between two and eight degrees Celsius, protected from light. Once dissolved, the solution is handled carefully because peptide bonds and the acyl modification can degrade under warm or alkaline conditions. Vials are inspected for cracks, and the powder is checked for color and uniformity before handling. Temperature excursions during shipping are a frequent reason for quality questions.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from truncated or oxidized forms. Mass spectrometry confirms the expected molecular weight, and peptide mapping after enzymatic digestion verifies the amino acid sequence. Water content is measured because residual moisture affects stability, and tests for aggregates or particulates are standard for injectable peptides. Circular dichroism can indicate whether the molecule has adopted an unexpected secondary structure in solution.
Research supply is often accompanied by a certificate of analysis listing chromatographic purity, mass confirmation, and storage conditions. Laboratories compare that document with an independent test when material is intended for bench work, since certificates describe a batch rather than an individual vial. Published studies usually state the source and purity of the peptide because small differences in purity can shift measured activity. Full analytical validation is rarely reported, which leaves batch-to-batch comparability an open question.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Identity and purity are judged through a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact peptide from truncated, oxidized, and deamidated variants, and the resulting peak-area percentages yield a purity figure. Electrospray ionization mass spectrometry confirms the expected molecular mass and can expose unanticipated modifications. Amino acid analysis and peptide mapping support sequence fidelity, while water content, pH, sterility, and bacterial endotoxin testing describe the physical and microbiological attributes of a finished lot.
Regulatory position depends on jurisdiction and on the form in which the material is sold. A branded product holds approval in the United States for a defined indication, and prescribing is confined to that label. Material marketed for laboratory research is not evaluated for human use and carries no such clearance. Independent verification therefore rests on certificates of analysis, third-party testing, and documented chain of custody. The substance also appears on the World Anti-Doping Agency prohibited list within the category covering growth hormone-releasing factors.
Homosexuality is illegal in Malaysia, and authorities have imposed punishments such as caning and imprisonment. Human trafficking and sex trafficking in Malaysia are significant problems. There have also been cases of vigilante executions and beatings against LGBT individuals in Malaysia. The illegality of homosexuality in Malaysia has also been the forefront of Anwar Ibrahim's sodomy trials, which Anwar has called politically motivated, a characterisation supported by the Working Group on Arbitrary Detention, along with Amnesty International and the Human Rights Watch. The death penalty is in use for serious crimes such as murder, terrorism, and drug trafficking, some of which were once mandatory. However, in July 2023, following the passing of the Abolition of Mandatory Death Penalty Act 2023, mandatory death penalty was abolished for all crimes in Malaysia, thereby allowing judges to impose the capital punishment at their own discretion and on a case-by-case basis. The new law also abolished all natural life imprisonment, replacing it with 30 to 40 years prison terms instead.
In early medieval Europe, some accounts stated that Common Vervain was used to staunch Jesus' wounds after his removal from the cross; hence names like "Holy Herb" or (e.g. in Wales) "Devil's bane". Because of the association with the Passion of Christ, it came to be used in ointments to drive out and repel "demonic" illnesses. Vervain flowers are engraved on cimaruta, Italian anti-stregheria charms. In the 1870 The History and Practice of Magic by "Paul Christian" (Jean-Baptiste Pitois) it is employed in the preparation of a mandragora charm. A Royal Navy Arabis-class sloop of the World War I era was named HMS Verbena, and in World War II a Group 1 Flower-class corvette bore the same name; a Group 2 vessel of the latter class was called HMS Vervain. The only Verbena widely found in England in a wild state is common vervain, though it is just as possible that the names reference the popular ornamental verbenas, such as the garden vervain.
channel protein A type of transmembrane protein whose shape forms an aqueous pore in a membrane, permitting the passage of specific solutes, often small ions, across the membrane in either or both directions.
Loss-of-function mutations, also called inactivating mutations, result in the gene product having less or no function (being partially or wholly inactivated). When the allele has a complete loss of function (null allele), it is often called an amorph or amorphic mutation in Muller's morphs schema. Phenotypes associated with such mutations are most often recessive. Exceptions are when the organism is haploid, or when the reduced dosage of a normal gene product is not enough for a normal phenotype (this is called haploinsufficiency). Examples of diseases caused by a loss-of-function mutation include Gitelman syndrome and cystic fibrosis. Gain-of-function mutations also called activating mutations, change the gene product such that its effect gets stronger (enhanced activation) or even is superseded by a different and abnormal function. When the new allele is created, a heterozygote containing the newly created allele as well as the original will express the new allele; genetically this defines the mutations as dominant phenotypes. Several of Muller's morphs correspond to the gain of function, including hypermorph (increased gene expression) and neomorph (novel function). Dominant negative mutations (also called anti-morphic mutations) have an altered gene product that acts antagonistically to the wild-type allele. These mutations usually result in an altered molecular function (often inactive) and are characterized by a dominant or semi-dominant phenotype.
Sources: en.wikipedia.org
Tyrosine kinases recruited to a receptor following hormone binding are receptor-associated tyrosine kinases and are involved in a number of signaling cascades, in particular those involved in cytokine signaling (but also others, including growth hormone). One such receptor-associated tyrosine kinase is Janus kinase (JAK), many of whose effects are mediated by STAT proteins. (See JAK-STAT pathway.)
Abraham Badu-Tawiah is a Ghanaian scientist who is a professor of chemistry at the Ohio State University. His research considers the development of mass spectrometry for the detection of disease. In 2017 he was awarded the American Chemical Society Arthur F. Findeis prize and in 2020 a Sloan Research Fellowship.
A multistep biochemical pathway like the Krebs cycle did not just self-organize on the surface of a mineral; it must have been preceded by simpler pathways. The Wood–Ljungdahl pathway is compatible with self-organization on a metal sulfide surface. Its key enzyme unit, carbon monoxide dehydrogenase/acetyl-CoA synthase, contains mixed nickel-iron-sulfur clusters in its reaction centers and catalyzes the formation of acetyl-CoA. However, prebiotic thiolated and thioester compounds are thermodynamically and kinetically unlikely to accumulate in the presumed prebiotic conditions of hydrothermal vents. One possibility is that cysteine and homocysteine may have reacted with nitriles from the Strecker reaction, forming catalytic thiol-rich polypeptides. It has been suggested that the iron-sulfur world hypothesis and RNA world hypothesis are not mutually exclusive as modern cellular processes do involve both metabolites and genetic molecules.
Sources: en.wikipedia.org
==== Rookie of the Year Award and early career (1991–1993) ==== The Astros invited Bagwell to major league camp in spring training of 1991. Bagwell, expecting for the club to assign him to their Triple-A affiliate in Tucson, enthused them with his play. Because they, too, already had an established major leaguer at third base in Ken Caminiti, they approached Bagwell about shifting to first base, which he accepted. Having not previously played the position as a regular, Bagwell received a crash course, playing minor league games in the morning and Astros games in the afternoon until Opening Day. Observed The Sporting News: "Rookie Jeff Bagwell never played first base before this spring, but the position is his to lose. It's up to his bat." Thus, Bagwell made the major league club without an assignment to AAA, making the uncommon jump from AA to the major leagues, and made his major league debut on Opening Day. On May 6, he hit the ninth-ever upper-deck home run at Three Rivers Stadium off Bob Kipper in a seventh-inning pinch hit appearance, estimated at 456 feet (139 m). Bagwell hit .350 in September. He finished the year hitting .294 with 15 home runs and 82 RBI while leading the Astros in several offensive categories. He was named the 1991 National League (NL) Rookie of the Year, the first Astros player to win the award, Baseball America's Rookie of the Year, The Sporting News Rookie of the Year and postseason All-Star and on the Topps' Rookie All-Star Team. Bagwell's power hike piqued the curiosity of many baseball observers.
== Career == Bhatia began her academic career in 1998, joining the bioengineering faculty at the University of California, San Diego (UCSD). As an assistant professor, she was awarded a five-year Packard Fellowship for Science and Engineering from the David and Lucile Packard Foundation in 1999. She was recognized with a "Teacher of the Year" award at the Jacobs School of Engineering in 2001, and was named an "Innovator under 35" by MIT Technology Review in 2003. Bhatia co-authored the first undergraduate textbook on tissue engineering, Tissue engineering (2004), written for senior-level and first-year graduate courses with Bernhard Palsson. She was a co-editor of Microdevices in Biology and Medicine (2009) and Biosensing: International Research and Development (2005). In 2005, she joined the MIT faculty in the Division of Health Sciences & Technology and the Department of Electrical Engineering and Computer Science. The Scientist named her a "Scientist to Watch" in 2006, and she became a Howard Hughes Medical Institute Investigator in 2008. Since 2013, Bhatia has expanded her affiliations within MIT and Harvard, including the Ludwig Center for Molecular Oncology (2013), the Broad Institute of MIT and Harvard (2014), the MIT Center for Neurobiological Engineering (2016), the Wyss Institute for Biologically Inspired Engineering (2018), and the Martin Trust Center for MIT Entrepreneurship (2022). Bhatia currently directs the Laboratory for Multiscale Regenerative Technologies and the Marble Center for Cancer Nanomedicine at MIT.
In cases of tumor-related hyperprolactinemia, prolactinoma is the most common culprit of consistently high levels of prolactin as well as the most common type of pituitary tumor. For non-tumor related hyperprolactinemia, the most common cause is medication-induced prolactin secretion. Particularly, antipsychotics have been linked to a majority of non-tumor related hyperprolactinemia cases due to their prolactin-rising and prolactin-sparing mechanisms. Typical antipsychotics have been shown to induce significant, dose-dependent increases in prolactin levels up to 10-fold the normal limit. Atypical antipsychotics vary in their ability to elevate prolactin levels; however, medications in this class, such as risperidone and paliperidone, carry the highest potential to induce hyperprolactinemia in a dose-dependent manner similar to typical antipsychotics.
Sources: en.wikipedia.org
Refrigeration between 2 and 8 degrees Celsius is typical, with protection from moisture and light. Dry, sealed containers help maintain stability over the labeled shelf life. Temperature cycling is usually minimized.
Reversed-phase high-performance liquid chromatography is commonly used to separate and quantify the peptide and its impurities. Mass spectrometry is often paired with it to confirm identity. Together they provide a profile of related substances.
Extreme pH values accelerate hydrolytic degradation of the peptide backbone. Buffered solutions in a near-neutral range generally slow this process. Solution age and temperature also affect the rate of breakdown.
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.